Skip to main content
TipRanks
Go Ultimate75% OFF

Aptevo Therapeutics (APVO) AI Stock Analysis

751 Followers
APVO

Aptevo Therapeutics

(NASDAQ:APVO)

Select Model
Rating:41Neutral
Price Target:$0.63â–²(14.96% Upside)
Action:reiterated
Date:11/13/26

The score is held down primarily by weak financial performance (no revenue, large recurring losses, and heavy cash burn) and very bearish technicals (price far below moving averages with negative momentum). Corporate events provide some offset via positive clinical/pipeline updates and incremental funding, but valuation support is limited given negative earnings and no dividend.

Positive Factors
Clinical progress in AMLImproved tolerability strengthens mipletamig’s development profile because fewer infusion reactions can support treatment adoption and trial execution. Maintaining planned dosing while reducing reactions also improves the candidate’s clinical usability and supports continued regulatory and commercial development in AML.
Negative Factors
No commercial revenueThe absence of revenue means Aptevo’s cost base is not yet supported by commercial activity, leaving financial performance dependent on clinical progress and future financing. Persistent losses also reduce earnings visibility and indicate that profitability remains dependent on successful product development and approval.

Aptevo Therapeutics (APVO) vs. SPDR S&P 500 ETF (SPY)

-100%-75%-50%-25%0%25%APVO-97.50%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.20M
Dividend Yield
―
Average Volume (3M)
113.17K
Price to Earnings (P/E)
-0.0
Beta (1Y)
-0.32
Revenue Growth
―
EPS Growth
99.31%
Country
US
Employees
33
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Aptevo Therapeutics Business Overview & Revenue Model

Company Description

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antib...

Aptevo Therapeutics Financial Statement Overview

Summary

Financial statements indicate very high operating risk: no revenue reported, large and persistent net losses (~$26M TTM), and substantial ongoing cash burn (operating cash flow about -$25M TTM). Debt is not extreme, but equity volatility and deeply negative ROE point to fragile capital stability and elevated dilution/financing risk.

Income Statement

9Very Negative

Balance Sheet

33Negative

Cash Flow

8Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue00003.11M12.29M
Gross Profit-116.00K-240.00K-352.00K03.11M12.29M
EBITDA-26.39M-25.73M-23.78M-18.08M7.92M-28.26M
Net Income-26.41M-25.97M-24.13M-17.41M8.03M-28.46M
Balance Sheet
Total Assets14.52M27.19M15.59M24.84M34.22M56.60M
Cash, Cash Equivalents and Short-Term Investments9.80M21.62M8.71M16.90M22.64M45.04M
Total Debt4.21M4.63M4.63M5.40M9.54M16.71M
Total Liabilities8.48M9.81M10.84M12.62M16.24M55.38M
Stockholders Equity6.04M17.38M4.75M12.22M17.97M1.22M
Cash Flow
Free Cash Flow-25.34M-25.59M-23.79M-11.73M-21.05M-22.39M
Operating Cash Flow-25.34M-25.59M-23.79M-11.73M-21.02M-21.68M
Investing Cash Flow0000-29.00K-713.00K
Financing Cash Flow25.73M38.50M15.60M6.00M-2.62M26.16M

Aptevo Therapeutics Technical Analysis

Technical Analysis SentimentNegative
Last Price0.55

Price Trends

50DMA1.57Negative
100DMA2.63Negative
200DMA3.95Negative

Market Momentum

MACD-0.29Positive
RSI10.75Positive
STOCH0.42Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APVO, the sentiment is Negative. The current price of 0.55 is below the 20-day moving average (MA) of 1.23, below the 50-day MA of 1.57, and below the 200-day MA of 3.95, indicating a bearish trend. The MACD of -0.29 indicates Positive momentum. The RSI at 10.75 is Positive, neither overbought nor oversold. The STOCH value of 0.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APVO.

Aptevo Therapeutics Risk Analysis

Aptevo Therapeutics disclosed 58 risk factors in its most recent earnings report. Aptevo Therapeutics reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk
1.Our efforts to develop radiopharmaceutical product candidates may expose us to additional development, manufacturing, supply chain, regulatory and safety risks.Q2, 2026

Aptevo Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

APVO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
LSTALSTA49Neutral$11.78M-0.60-164.72%―-90.65%11.37%
ALLRALLR44Neutral$14.00M-0.89-349.08%――38.64%
MBRXMBRX44Neutral$7.58M-0.64-81.19%――99.02%
APVOAPVO41Neutral$993.08K-0.00-290.07%――99.31%
EDSAEDSA40Underperform$25.54M-1.15-124.21%――-27.34%

* Healthcare Sector Average

Performance Comparison

0%250%500%750%APVOLSTAMBRXEDSAALLRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
APVO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
APVOAptevo0.55-23.21-97.69%
LSTALisata Therapeutics, Inc.1.09-0.96-46.83%
MBRXMoleculin Biotech7.14-202.86-96.60%
EDSAEdesa Biotech1.890.158.62%
ALLRAllarity Therapeutics, Inc.0.88-0.26-23.25%

Aptevo Therapeutics Corporate Events

Private Placements and Financing

Aptevo Therapeutics Announces Warrant Exercise Financing Agreement

Positive
Nov 12, 2026

On November 11, 2026, Aptevo entered agreements with certain warrant holders who agreed to exercise existing warrants for up to 2,777,778 shares at a reduced price of $1.08 per share. The transaction closed on November 12, 2026, and the company recei...

Business Operations and StrategyProduct-Related Announcements

Aptevo Presents New Multispecific Immunotherapy Data at SITC 2026

Positive
Nov 9, 2026

On November 7, 2026, Aptevo presented new preclinical data from its next-generation multispecific platform at SITC 2026, showing that APVO451 and APVO452 promoted cancer-cell killing and T-cell activation under immunosuppressive conditions. The data...

Product-Related Announcements

Aptevo Reports Improved Mipletamig Tolerability in Frontline AML

Positive
Nov 5, 2026

On November 5, 2026, Aptevo announced that successive refinements to mipletamig’s priming-dose regimen substantially reduced infusion-related reactions in frontline AML. The improvement built on the candidate’s favorable safety and tolerability profi...

Business Operations and StrategyProduct-Related Announcements

Aptevo highlights promising AML transplant outcomes with mipletamig

Positive
Oct 26, 2026

On October 26, 2026, Aptevo reported that ten of forty-seven frontline acute myeloid leukemia patients initially considered unfit for intensive chemotherapy advanced to allogeneic stem cell transplant after treatment with mipletamig plus venetoclax a...

Business Operations and StrategyRegulatory Filings and Compliance

Aptevo Therapeutics Reports New Material Definitive Agreement

Neutral
Oct 23, 2026

In a recent filing, Aptevo Therapeutics reported that information related to its entry into a material definitive agreement has been cross-referenced within its current report on Form 8-K. The disclosure indicates that key terms of the agreement are...

Business Operations and Strategy

Aptevo to Present CD40 Multispecific Cancer Platform

Positive
Oct 14, 2026

On October 14, 2026, Aptevo Therapeutics announced plans to showcase its multispecific platform at the Society for Immunotherapy of Cancer 2026 Annual Meeting, scheduled for November 4–8, 2026, in Phoenix, Arizona. The presentation will highlight Apt...

Business Operations and StrategyProduct-Related Announcements

Aptevo Advances Next-Generation Trispecific Immuno-Oncology Programs

Positive
Sep 24, 2026

On September 24, 2026, Aptevo Therapeutics announced it is advancing its next-generation trispecific immuno-oncology programs, optimizing several candidates for reliable, scalable manufacturing. The company’s lead trispecific candidate, APVO451, is b...

Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings

Aptevo Shareholders Approve Equity Issuance, Reject Charter Changes

Positive
Sep 23, 2026

On September 22, 2026, Aptevo Therapeutics stockholders held a special meeting at which they rejected proposed technical and administrative amendments to the company’s Amended and Restated Certificate of Incorporation, despite a majority of votes cas...

Business Operations and StrategyProduct-Related Announcements

Aptevo Reports Promising Mipletamig Data in TP53-Mutant AML

Positive
Sep 3, 2026

On September 3, 2026, Aptevo Therapeutics reported new data showing a 93% clinical benefit rate for its lead drug candidate mipletamig, used in combination with venetoclax and azacitidine, in 14 evaluable frontline acute myeloid leukemia patients wit...

Business Operations and StrategyExecutive/Board ChangesShareholder Meetings

Aptevo Shareholders Back Board, Auditor and Incentive Plan

Positive
Aug 21, 2026

On August 21, 2026, Aptevo Therapeutics Inc. held its Annual Meeting of Stockholders, at which shareholders elected Zsolt Harsanyi, Ph.D., and Barbara Lopez Kunz to the board to serve until the 2029 annual meeting, and ratified Baker Tilly US, LLP as...

Private Placements and Financing

Aptevo Therapeutics Raises Capital Through Warrant-Induced Financing

Neutral
Aug 13, 2026

On August 12, 2026, Aptevo Therapeutics entered into warrant inducement agreements and a securities purchase agreement with certain existing warrant holders, leading to the exercise of prior warrants at a reduced price of $4.03 per share and the issu...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026